Pharmaceutics (Feb 2023)

Cannabidiol-Loaded Extracellular Vesicles from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Paclitaxel-Induced Peripheral Neuropathy

  • Anil Kumar Kalvala,
  • Arvind Bagde,
  • Peggy Arthur,
  • Tanmay Kulkarni,
  • Santanu Bhattacharya,
  • Sunil Surapaneni,
  • Nil Kumar Patel,
  • Ramesh Nimma,
  • Aragaw Gebeyehu,
  • Nagavendra Kommineni,
  • Yan Li,
  • David G. Meckes,
  • Li Sun,
  • Bipika Banjara,
  • Keb Mosley-Kellum,
  • Thanh Cong Dinh,
  • Mandip Singh

DOI
https://doi.org/10.3390/pharmaceutics15020554
Journal volume & issue
Vol. 15, no. 2
p. 554

Abstract

Read online

In cancer patients, chronic paclitaxel (PTX) treatment causes excruciating pain, limiting its use in cancer chemotherapy. The neuroprotective potential of synthetic cannabidiol (CBD) and CBD formulated in extracellular vesicles (CBD-EVs) isolated from human umbilical cord derived mesenchymal stem cells was investigated in C57BL/6J mice with PTX-induced neuropathic pain (PIPN). The particle size of EVs and CBD-EVs, surface roughness, nanomechanical properties, stability, and release studies were all investigated. To develop neuropathy in mice, PTX (8 mg/kg, i.p.) was administered every other day (four doses). In terms of decreasing mechanical and thermal hypersensitivity, CBD-EVs treatment was superior to EVs treatment or CBD treatment alone (p p < 0.001). Studies inhibiting the AMPK and 5HT1A receptors found that CBD did not influence the neurobehavioral or mitochondrial function of PIPN. Based on these results, we hypothesize that CBD and CBD-EVs mitigated PIPN by modulating AMPK and mitochondrial function.

Keywords